Keeping PACE with β blockers in COPD
- 22 January 2026
- journal article
- Published by Elsevier in The Lancet Respiratory Medicine
- Vol. 14 (3) , 188-189
Abstract
No abstract availableFunding Information
- National Institutes of Health
This publication has 8 references indexed in Scilit:
- Bisoprolol to prevent adverse cardiac events (PACE) in COPD: a multicentre, double-blind, randomised, controlled, phase 3 trialThe Lancet Respiratory Medicine, 2026
- Beta-Blockers after Myocardial Infarction without Reduced Ejection FractionNew England Journal of Medicine, 2025
- Beta-Blockers after Myocardial Infarction in Patients without Heart FailureNew England Journal of Medicine, 2025
- Beta-Blocker Interruption or Continuation after Myocardial InfarctionNew England Journal of Medicine, 2024
- Bisoprolol in Patients With Chronic Obstructive Pulmonary Disease at High Risk of ExacerbationJAMA, 2024
- β-Blocker Use and Clinical Outcomes in Patients With COPD Following Acute Myocardial InfarctionJAMA Network Open, 2024
- Metoprolol for the Prevention of Acute Exacerbations of COPDNew England Journal of Medicine, 2019
- Chronic obstructive pulmonary disease and cardiovascular diseaseTranslational Research, 2013